An observational study in Diabete Type 1, sponsored by University of Bari. Recruiting at 1 site in Italy. Open to participants aged 1 Year to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by University of Bari · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 61 studies in Celiac Disease with a site in Italy — 14 open to participants now, 16 under way, none of them phase 3. Celiac Disease · Italy.
Among the 61 studies in Celiac Disease with a site in Italy, this one is the 3rd largest by planned enrollment of the 26 observational ones that give a count, is one of 3 that started in 2026, is one of 26 observational ones, reaches primary completion later than 8 of the 15 other live ones, and was the 58th registered.
353 studies on the registry are indexed under Celiac Disease; 78 are open to participants now.
Browse Celiac Disease studies →14 of the 61 studies in Celiac Disease with a site in Italy are open now. Recruiting first, the newest first:
University of Palermo · Sites in Italy
Ages 1–14
University of Palermo · Sites in Italy
Ages 18+
University of Pavia · Sites in Italy
Ages 18+
Istituti Clinici Scientifici Maugeri SpA · Sites in Italy
Ages 18+
Istituti Clinici Scientifici Maugeri SpA · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 48 Celiac Disease studies recruiting now, 24 (50%) set no upper age limit and 19 (40%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.
This study: 1 Year to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
61 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 3 started in 2026.
This study's planned enrollment of 600 is above the median of 185 across 134 observational studies indexed under Celiac Disease.
Median enrollment 50 across the 35 interventional studies, 207 across the 26 observational. Of the 30 that completed or were terminated, 1 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 61 have an industry lead sponsor. The 10 most frequent:
University of Bari is the lead sponsor of 76 studies on the registry; 12 are open to participants now.
University of Bari has 3 studies filed under Celiac Disease — fewer than ten, so there is no comparison to draw.
4 of the studies in Celiac Disease with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07862101University of BariStrategy For Assessing The Risk Of Type 1 Diabetes In Pediatric Celiac Patients | 2026-12-30 |
| NCT07915063Istituti Clinici Scientifici Maugeri SpAImpact of Mediterranean Diet and Processed Food Consumption on Gastrointestinal Symptoms in Coeliac Patients on a Gluten-Free Diet | 2026-12-31 |
| NCT03017716University of PalermoInflammatory Back Pain and Gluten Free Diet | 2027-01-01 |
| NCT07584473University of PalermoNCWS or IBS/FD in Relatives of CD Patients | 2027-04-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 61 studies in Celiac Disease with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Celiac disease (CD) and type 1 diabetes mellitus (T1D) are chronic autoimmune disorders that frequently co-occur, largely due to shared genetic susceptibility, particularly HLA-DQ2 and HLA-DQ8 alleles. In Italy, approximately 300,000 individuals are affected by T1D, with a prevalence of 0.5% in the general population and 0.22% in the pediatric population. The annual incidence among children is 12.26 per 100,000, with boys affected more frequently than girls (13.13 vs. 11.35 per 100,000). Alarmingly, 25-40% of pediatric patients present with diabetic ketoacidosis (DKA) at disease onset. International prospective studies, such as the Environmental Determinants of Diabetes in the Young (TEDDY) study, have demonstrated that symptoms are poor predictors of CD autoimmunity, emphasizing the need for structured population-based screening strategies. Similarly, in T1D, the appearance of disease-specific autoantibodies-such as anti-GAD, insulin autoantibodies (IAA), IA-2A, and ZnT8A-can precede the onset of clinical disease by years. Identifying these markers enables early risk stratification, timely monitoring, and potential enrollment in immunomodulatory prevention trials, including those organized by TrialNet.
In this context, an observational study is being conducted at the Pediatric Department of the University of Bari. It involves the prospective screening of children (ages 1 to 18 years) with a confirmed diagnosis of celiac disease for T1D-associated autoantibodies. The study aims to enroll 600 CD patients over one year, with an anticipated 80% participation rate among eligible families.
Celiac disease (CD) and type 1 diabetes mellitus (T1D) are chronic autoimmune disorders that frequently co-occur, largely due to shared genetic susceptibility, particularly HLA-DQ2 and HLA-DQ8 alleles. In Italy, approximately 300,000 individuals are affected by T1D, with a prevalence of 0.5% in the general population and 0.22% in the pediatric population. The annual incidence among children is 12.26 per 100,000, with boys affected more frequently than girls (13.13 vs. 11.35 per 100,000). Alarmingly, 25-40% of pediatric patients present with diabetic ketoacidosis (DKA) at disease onset.
Current guidelines recommend screening for celiac disease with tissue transglutaminase autoantibody (TGA) testing in both symptomatic individuals and asymptomatic individuals with high-risk features. These include a family history of CD, coexisting autoimmune disorders such as T1D, and specific genetic syndromes. While gastrointestinal symptoms like diarrhea, abdominal distension, vomiting, and malabsorption often prompt CD evaluation, many patients-more than half-are asymptomatic at diagnosis. This highlights a significant limitation in symptom-based screening approaches.
International prospective studies, such as the Environmental Determinants of Diabetes in the Young (TEDDY) study, have demonstrated that symptoms are poor predictors of CD autoimmunity, emphasizing the need for structured population-based screening strategies. Similarly, in T1D, the appearance of disease-specific autoantibodies-such as anti-GAD, insulin autoantibodies (IAA), IA-2A, and ZnT8A-can precede the onset of clinical disease by years. Identifying these markers enables early risk stratification, timely monitoring, and potential enrollment in immunomodulatory prevention trials, including those organized by TrialNet.
In this context, an observational study is being conducted at the Pediatric Department of the University of Bari. It involves the prospective screening of children (ages 1 to 18 years) with a confirmed diagnosis of celiac disease for T1D-associated autoantibodies. The study aims to enroll 600 CD patients over one year, with an anticipated 80% participation rate among eligible families. This initiative seeks to identify early serological markers of T1D in a high-risk population and to inform preventive strategies aimed at reducing the burden of severe complications such as DKA.
Children with biopbsy-confirmed CD
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Known diagnosis of type 1 diabetes.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
600 pediatric subjects will be enrolled, all with a confirmed diagnosis of celiac disease according to the 2020 ESOPGHAN criteria.
Screening of celiac paediatric patients
The aim of the CARES-T1D project is to determine the prevalence of type 1 diabetes-associated autoantibodies (T1D) in pediatric subjects with CD to assess the frequency with which these immunologic biomarkers occur in this specific population. The plan is to screen all children in follow-up at our out-patient celiac clinic for diabetes specific autoantibodies. The parents will be informed about the study and invited to take part in the study during the scheduled appointment; a written informed consent will be signed by parents. The screening activity will be carried out over a 1-year period. It is expected that at least 80% of the parents will give their informed consent to participation in the study. Accordingly, about 480 celiac patients will be screened for the four biochemical autoantibodies predicting T1D, i.e. insulin autoantibodies (IAA)
Time frame: baseline
TD1 in CD
Secondary aims are a) to assess the frequency of multiple autoantibody positivity and classify children according to TrialNet T1D staging; b) to identify predictors of antibody positivity; c) to evaluate progression rates to clinical T1D in the follow-up phase; d) to reduce the incidence of DKA by promoting early detection; d) to validate a scalable screening protocol for T1D risk in pediatric CD populations.
Time frame: 12 months
Plan to share: Undecided
Started Jan 2026 (actual). Primary completion is estimated for Dec 2026, 11 months after the start.
Of 48 observational studies under Celiac Disease, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 83. This study's planned 11 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Bari